
Therapeutic Vaccines Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Cancer Vaccines, Infectious Disease Vaccines, and Others), Technology (Allogenic Vaccines and Autol
Description
The therapeutic vaccines market size is expected to grow from US$ 1.24 billion in 2024 to US$ 2.93 billion by 2031; it is projected to register a CAGR of 13.0% during 2024-2031. The rising prevalence of chronic diseases, and increasing investments and funding for vaccine development are noteworthy factors contributing to the expansion of the therapeutic vaccines market size. However, regulatory challenges hinder the therapeutic vaccines market growth.
Developing vaccines against emerging pathogens that possess the potential to cause pandemics is not feasible using conventional technologies. As a result, it is important to develop platforms that can respond rapidly to pandemic threats and adapt effectively to measures taken to tackle emerging variants. Innovative vaccine platformsβsuch as mRNA vaccines, immuno-material-based vaccine technology, nano-drug delivery systems, and viral vector-based vaccinesβare revolutionizing the development of therapeutic vaccines. Further, the shift toward more efficient and customizable vaccine technologies has enabled the development of vaccines that can target several diseases, including cancers, autoimmune conditions, and infectious diseases. The success of mRNA COVID-19 vaccine technology showcases promises in the potential of mRNA technology for therapeutic applications beyond infectious diseases, including cancer and chronic infections. These platforms allow for quicker, more flexible, and better scalable vaccine production, accelerating the development of new therapeutic vaccines.
Researchers are developing novel platforms for future applications. For instance, a research team at the Wyss Institute at Harvard University is developing a pioneering vaccine platform known as OMNIVAX. This first-in-class immuno-material-based vaccine technology aims to create safe and effective therapeutic and prophylactic vaccines against viral and bacterial infections. Upon injection, OMNIVAX vaccines establish a scaffold to attract dendritic immune cells, programming them to target a specific antigen. The cells are then released, followed by their migration to nearby lymph nodes, where they initiate a systemic and prolonged immune response. Using modular technology, multiple antigens can be incorporated into a single OMNIVAX vaccine. The advancements in vaccine technology are likely to bring new trends in the therapeutic vaccines market in the coming years.
End User-Based Insights
Based on end user, the therapeutic vaccines market is segmented into hospitals, clinics, and others. The hospitals segment held the largest therapeutic vaccines market share in 2024. Therapeutic vaccines are increasingly being recognized as a critical part of the treatment of cancer and other chronic diseases, which are frequently managed in hospital settings. Hospitals are equipped with the advanced infrastructure required to administer specialized therapies against cancer and autoimmune diseases. As the prevalence of chronic diseases, including cancer, continues to rise globally, hospitals generate a persistent demand for these treatments. Hospitals offer comprehensive care, including diagnostic services, treatment, and post-therapy monitoring, all of which are crucial for patients undergoing therapeutic vaccine treatments. Additionally, an upsurge in hospital-based research and clinical trials contributes to the expansion of the therapeutic vaccines market for this segment. Many therapeutic vaccines undergo trials within hospital environments, enabling healthcare professionals to stay updated on the development of new vaccines and treatments, fueling the therapeutic vaccines market growth.
World Health Organization's (WHO), Global Cancer Facts & Figures, and the American Cancer Society are among the primary and secondary sources referred to while preparing the therapeutic vaccines market report.
Reasons to buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the therapeutic vaccines market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the therapeutic vaccines market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Developing vaccines against emerging pathogens that possess the potential to cause pandemics is not feasible using conventional technologies. As a result, it is important to develop platforms that can respond rapidly to pandemic threats and adapt effectively to measures taken to tackle emerging variants. Innovative vaccine platformsβsuch as mRNA vaccines, immuno-material-based vaccine technology, nano-drug delivery systems, and viral vector-based vaccinesβare revolutionizing the development of therapeutic vaccines. Further, the shift toward more efficient and customizable vaccine technologies has enabled the development of vaccines that can target several diseases, including cancers, autoimmune conditions, and infectious diseases. The success of mRNA COVID-19 vaccine technology showcases promises in the potential of mRNA technology for therapeutic applications beyond infectious diseases, including cancer and chronic infections. These platforms allow for quicker, more flexible, and better scalable vaccine production, accelerating the development of new therapeutic vaccines.
Researchers are developing novel platforms for future applications. For instance, a research team at the Wyss Institute at Harvard University is developing a pioneering vaccine platform known as OMNIVAX. This first-in-class immuno-material-based vaccine technology aims to create safe and effective therapeutic and prophylactic vaccines against viral and bacterial infections. Upon injection, OMNIVAX vaccines establish a scaffold to attract dendritic immune cells, programming them to target a specific antigen. The cells are then released, followed by their migration to nearby lymph nodes, where they initiate a systemic and prolonged immune response. Using modular technology, multiple antigens can be incorporated into a single OMNIVAX vaccine. The advancements in vaccine technology are likely to bring new trends in the therapeutic vaccines market in the coming years.
End User-Based Insights
Based on end user, the therapeutic vaccines market is segmented into hospitals, clinics, and others. The hospitals segment held the largest therapeutic vaccines market share in 2024. Therapeutic vaccines are increasingly being recognized as a critical part of the treatment of cancer and other chronic diseases, which are frequently managed in hospital settings. Hospitals are equipped with the advanced infrastructure required to administer specialized therapies against cancer and autoimmune diseases. As the prevalence of chronic diseases, including cancer, continues to rise globally, hospitals generate a persistent demand for these treatments. Hospitals offer comprehensive care, including diagnostic services, treatment, and post-therapy monitoring, all of which are crucial for patients undergoing therapeutic vaccine treatments. Additionally, an upsurge in hospital-based research and clinical trials contributes to the expansion of the therapeutic vaccines market for this segment. Many therapeutic vaccines undergo trials within hospital environments, enabling healthcare professionals to stay updated on the development of new vaccines and treatments, fueling the therapeutic vaccines market growth.
World Health Organization's (WHO), Global Cancer Facts & Figures, and the American Cancer Society are among the primary and secondary sources referred to while preparing the therapeutic vaccines market report.
Reasons to buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the therapeutic vaccines market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the therapeutic vaccines market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Table of Contents
207 Pages
- 1. Introduction
- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation
- 2. Executive Summary
- 2.1 Key Insights
- 3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
- 4. Therapeutic Vaccines Market Landscape
- 4.1 Overview
- 4.2 PEST Analysis
- 5. Therapeutic Vaccines Market β Key Market Dynamics
- 5.1 Therapeutic Vaccines Market β Key Market Dynamics
- 5.2 Market Drivers
- 5.2.1 Rising Prevalence of Chronic Conditions
- 5.2.2 Increasing Investments and Funding for Vaccine Development
- 5.3 Market Restraints
- 5.3.1 Regulatory Challenges
- 5.4 Market Opportunities
- 5.4.1 Extending Product Pipeline
- 5.5 Future Trends
- 5.5.1 Advancements in Vaccine Technology
- 5.6 Impact of Drivers and Restraints:
- 6. Therapeutic Vaccines Market β Global Market Analysis
- 6.1 Therapeutic Vaccines Market Revenue (US$ Thousand), 2021β2031
- 6.2 Therapeutic Vaccines Market Forecast Analysis
- 7. Therapeutic Vaccines Market Analysis β by Product
- 7.1 Cancer Vaccines
- 7.1.1 Overview
- 7.1.2 Cancer Vaccines: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 7.2 Infectious Disease Vaccines
- 7.2.1 Overview
- 7.2.2 Infectious Disease Vaccines: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 7.3 Others
- 7.3.1 Overview
- 7.3.2 Others: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 8. Therapeutic Vaccines Market Analysis β by Technology
- 8.1 Allogenic Vaccine
- 8.1.1 Overview
- 8.1.2 Allogenic Vaccine: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 8.2 Autologous Vaccine
- 8.2.1 Overview
- 8.2.2 Autologous Vaccine: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 9. Therapeutic Vaccines Market Analysis β by End User
- 9.1 Hospitals
- 9.1.1 Overview
- 9.1.2 Hospitals: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 9.2 Clinics
- 9.2.1 Overview
- 9.2.2 Clinics: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 9.3 Others
- 9.3.1 Overview
- 9.3.2 Others: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10. Therapeutic Vaccines Market β Geographical Analysis
- 10.1 North America
- 10.1.1 North America Therapeutic Vaccines Market Overview
- 10.1.2 North America: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.1.2.1 North America: Therapeutic Vaccines Market β Revenue and Forecast Analysis β by Product
- 10.1.2.2 North America: Therapeutic Vaccines Market β Revenue and Forecast Analysis β by Technology
- 10.1.2.3 North America: Therapeutic Vaccines Market β Revenue and Forecast Analysis β by End User
- 10.1.3 North America: Therapeutic Vaccines Market β Revenue and Forecast Analysis β by Country
- 10.1.3.1 United States: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.1.3.1.1 United States: Therapeutic Vaccines Market Breakdown, by Product
- 10.1.3.1.2 United States: Therapeutic Vaccines Market Breakdown, by Technology
- 10.1.3.1.3 United States: Therapeutic Vaccines Market Breakdown, by End User
- 10.1.3.2 Canada: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.1.3.2.1 Canada: Therapeutic Vaccines Market Breakdown, by Product
- 10.1.3.2.2 Canada: Therapeutic Vaccines Market Breakdown, by Technology
- 10.1.3.2.3 Canada: Therapeutic Vaccines Market Breakdown, by End User
- 10.1.3.3 Mexico: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.1.3.3.1 Mexico: Therapeutic Vaccines Market Breakdown, by Product
- 10.1.3.3.2 Mexico: Therapeutic Vaccines Market Breakdown, by Technology
- 10.1.3.3.3 Mexico: Therapeutic Vaccines Market Breakdown, by End User
- 10.2 Europe
- 10.2.1 Europe Therapeutic Vaccines Market Overview
- 10.2.2 Europe: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.2.2.1 Europe: Therapeutic Vaccines Market β Revenue and Forecast Analysis β by Product
- 10.2.2.2 Europe: Therapeutic Vaccines Market β Revenue and Forecast Analysis β by Technology
- 10.2.2.3 Europe: Therapeutic Vaccines Market β Revenue and Forecast Analysis β by End User
- 10.2.3 Europe: Therapeutic Vaccines Market β Revenue and Forecast Analysis β by Country
- 10.2.3.1 Germany: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.2.3.1.1 Germany: Therapeutic Vaccines Market Breakdown, by Product
- 10.2.3.1.2 Germany: Therapeutic Vaccines Market Breakdown, by Technology
- 10.2.3.1.3 Germany: Therapeutic Vaccines Market Breakdown, by End User
- 10.2.3.2 United Kingdom: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.2.3.2.1 United Kingdom: Therapeutic Vaccines Market Breakdown, by Product
- 10.2.3.2.2 United Kingdom: Therapeutic Vaccines Market Breakdown, by Technology
- 10.2.3.2.3 United Kingdom: Therapeutic Vaccines Market Breakdown, by End User
- 10.2.3.3 France: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.2.3.3.1 France: Therapeutic Vaccines Market Breakdown, by Product
- 10.2.3.3.2 France: Therapeutic Vaccines Market Breakdown, by Technology
- 10.2.3.3.3 France: Therapeutic Vaccines Market Breakdown, by End User
- 10.2.3.4 Italy: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.2.3.4.1 Italy: Therapeutic Vaccines Market Breakdown, by Product
- 10.2.3.4.2 Italy: Therapeutic Vaccines Market Breakdown, by Technology
- 10.2.3.4.3 Italy: Therapeutic Vaccines Market Breakdown, by End User
- 10.2.3.5 Spain: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.2.3.5.1 Spain: Therapeutic Vaccines Market Breakdown, by Product
- 10.2.3.5.2 Spain: Therapeutic Vaccines Market Breakdown, by Technology
- 10.2.3.5.3 Spain: Therapeutic Vaccines Market Breakdown, by End User
- 10.2.3.6 Rest of Europe: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.2.3.6.1 Rest of Europe: Therapeutic Vaccines Market Breakdown, by Product
- 10.2.3.6.2 Rest of Europe: Therapeutic Vaccines Market Breakdown, by Technology
- 10.2.3.6.3 Rest of Europe: Therapeutic Vaccines Market Breakdown, by End User
- 10.3 Asia Pacific
- 10.3.1 Asia Pacific Therapeutic Vaccines Market Overview
- 10.3.2 Asia Pacific: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.3.2.1 Asia Pacific: Therapeutic Vaccines Market β Revenue and Forecast Analysis β by Product
- 10.3.2.2 Asia Pacific: Therapeutic Vaccines Market β Revenue and Forecast Analysis β by Technology
- 10.3.2.3 Asia Pacific: Therapeutic Vaccines Market β Revenue and Forecast Analysis β by End User
- 10.3.3 Asia Pacific: Therapeutic Vaccines Market β Revenue and Forecast Analysis β by Country
- 10.3.3.1 China: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.3.3.1.1 China: Therapeutic Vaccines Market Breakdown, by Product
- 10.3.3.1.2 China: Therapeutic Vaccines Market Breakdown, by Technology
- 10.3.3.1.3 China: Therapeutic Vaccines Market Breakdown, by End User
- 10.3.3.2 Japan: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.3.3.2.1 Japan: Therapeutic Vaccines Market Breakdown, by Product
- 10.3.3.2.2 Japan: Therapeutic Vaccines Market Breakdown, by Technology
- 10.3.3.2.3 Japan: Therapeutic Vaccines Market Breakdown, by End User
- 10.3.3.3 India: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.3.3.3.1 India: Therapeutic Vaccines Market Breakdown, by Product
- 10.3.3.3.2 India: Therapeutic Vaccines Market Breakdown, by Technology
- 10.3.3.3.3 India: Therapeutic Vaccines Market Breakdown, by End User
- 10.3.3.4 South Korea: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.3.3.4.1 South Korea: Therapeutic Vaccines Market Breakdown, by Product
- 10.3.3.4.2 South Korea: Therapeutic Vaccines Market Breakdown, by Technology
- 10.3.3.4.3 South Korea: Therapeutic Vaccines Market Breakdown, by End User
- 10.3.3.5 Australia: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.3.3.5.1 Australia: Therapeutic Vaccines Market Breakdown, by Product
- 10.3.3.5.2 Australia: Therapeutic Vaccines Market Breakdown, by Technology
- 10.3.3.5.3 Australia: Therapeutic Vaccines Market Breakdown, by End User
- 10.3.3.6 Rest of APAC: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.3.3.6.1 Rest of APAC: Therapeutic Vaccines Market Breakdown, by Product
- 10.3.3.6.2 Rest of APAC: Therapeutic Vaccines Market Breakdown, by Technology
- 10.3.3.6.3 Rest of APAC: Therapeutic Vaccines Market Breakdown, by End User
- 10.4 Middle East & Africa
- 10.4.1 Middle East & Africa Therapeutic Vaccines Market Overview
- 10.4.2 Middle East & Africa: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.4.2.1 Middle East & Africa: Therapeutic Vaccines Market β Revenue and Forecast Analysis β by Product
- 10.4.2.2 Middle East & Africa: Therapeutic Vaccines Market β Revenue and Forecast Analysis β by Technology
- 10.4.2.3 Middle East & Africa: Therapeutic Vaccines Market β Revenue and Forecast Analysis β by End User
- 10.4.3 Middle East & Africa: Therapeutic Vaccines Market β Revenue and Forecast Analysis β by Country
- 10.4.3.1 Saudi Arabia: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.4.3.1.1 Saudi Arabia: Therapeutic Vaccines Market Breakdown, by Product
- 10.4.3.1.2 Saudi Arabia: Therapeutic Vaccines Market Breakdown, by Technology
- 10.4.3.1.3 Saudi Arabia: Therapeutic Vaccines Market Breakdown, by End User
- 10.4.3.2 South Africa: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.4.3.2.1 South Africa: Therapeutic Vaccines Market Breakdown, by Product
- 10.4.3.2.2 South Africa: Therapeutic Vaccines Market Breakdown, by Technology
- 10.4.3.2.3 South Africa: Therapeutic Vaccines Market Breakdown, by End User
- 10.4.3.3 United Arab Emirates: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.4.3.3.1 United Arab Emirates: Therapeutic Vaccines Market Breakdown, by Product
- 10.4.3.3.2 United Arab Emirates: Therapeutic Vaccines Market Breakdown, by Technology
- 10.4.3.3.3 United Arab Emirates: Therapeutic Vaccines Market Breakdown, by End User
- 10.4.3.4 Rest of Middle East & Africa: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.4.3.4.1 Rest of Middle East & Africa: Therapeutic Vaccines Market Breakdown, by Product
- 10.4.3.4.2 Rest of Middle East & Africa: Therapeutic Vaccines Market Breakdown, by Technology
- 10.4.3.4.3 Rest of Middle East & Africa: Therapeutic Vaccines Market Breakdown, by End User
- 10.5 South & Central America
- 10.5.1 South & Central America Therapeutic Vaccines Market Overview
- 10.5.2 South & Central America: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.5.2.1 South & Central America: Therapeutic Vaccines Market β Revenue and Forecast Analysis β by Product
- 10.5.2.2 South & Central America: Therapeutic Vaccines Market β Revenue and Forecast Analysis β by Technology
- 10.5.2.3 South & Central America: Therapeutic Vaccines Market β Revenue and Forecast Analysis β by End User
- 10.5.3 South & Central America: Therapeutic Vaccines Market β Revenue and Forecast Analysis β by Country
- 10.5.3.1 Brazil: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.5.3.1.1 Brazil: Therapeutic Vaccines Market Breakdown, by Product
- 10.5.3.1.2 Brazil: Therapeutic Vaccines Market Breakdown, by Technology
- 10.5.3.1.3 Brazil: Therapeutic Vaccines Market Breakdown, by End User
- 10.5.3.2 Argentina: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.5.3.2.1 Argentina: Therapeutic Vaccines Market Breakdown, by Product
- 10.5.3.2.2 Argentina: Therapeutic Vaccines Market Breakdown, by Technology
- 10.5.3.2.3 Argentina: Therapeutic Vaccines Market Breakdown, by End User
- 10.5.3.3 Rest of South & Central America: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- 10.5.3.3.1 Rest of South & Central America: Therapeutic Vaccines Market Breakdown, by Product
- 10.5.3.3.2 Rest of South & Central America: Therapeutic Vaccines Market Breakdown, by Technology
- 10.5.3.3.3 Rest of South & Central America: Therapeutic Vaccines Market Breakdown, by End User
- 11. Therapeutic Vaccines Market β Industry Landscape
- 11.1 Overview
- 11.2 Growth Strategies in the Therapeutic Vaccines Market
- 11.3 Organic Growth Strategies
- 11.3.1 Overview
- 11.4 Inorganic Growth Strategies
- 11.4.1 Overview
- 12. Company Profiles
- 12.1 Dendreon
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
- 12.2 BioNTech SE
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
- 12.3 Serum Institute of India Pvt. Ltd
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
- 12.4 Merck & Co Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
- 12.5 Amgen Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
- 12.6 ISA Pharmaceuticals BV
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 INOVIO Pharmaceuticals Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
- 12.8 Transgene SA
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
- 12.9 THERAVECTYS SA
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
- 12.10 CureVac SE
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
- 13. Appendix
- 13.1 About The Insight Partners
- 13.2 Glossary of Terms
- LIST OF TABLES
- Table 1. Therapeutic Vaccines Market Segmentation
- Table 2. North America: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 3. North America: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 4. North America: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 5. United States: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 6. United States: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 7. United States: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 8. Canada: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 9. Canada: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 10. Canada: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 11. Mexico: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 12. Mexico: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 13. Mexico: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 14. Europe: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 15. Europe: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 16. Europe: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 17. Germany: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 18. Germany: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 19. Germany: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 20. United Kingdom: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 21. United Kingdom: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 22. United Kingdom: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 23. France: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 24. France: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 25. France: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 26. Italy: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 27. Italy: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 28. Italy: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 29. Spain: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 30. Spain: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 31. Spain: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 32. Rest of Europe: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 33. Rest of Europe: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 34. Rest of Europe: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 35. Asia Pacific: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 36. Asia Pacific: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 37. Asia Pacific: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 38. China: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 39. China: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 40. China: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 41. Japan: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 42. Japan: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 43. Japan: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 44. India: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 45. India: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 46. India: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 47. South Korea: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 48. South Korea: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 49. South Korea: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 50. Australia: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 51. Australia: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 52. Australia: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 53. Rest of APAC: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 54. Rest of APAC: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 55. Rest of APAC: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 56. Middle East & Africa: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 57. Middle East & Africa: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 58. Middle East & Africa: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 59. Saudi Arabia: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 60. Saudi Arabia: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 61. Saudi Arabia: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 62. South Africa: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 63. South Africa: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 64. South Africa: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 65. United Arab Emirates: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 66. United Arab Emirates: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 67. United Arab Emirates: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 68. Rest of Middle East & Africa: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 69. Rest of Middle East & Africa: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 70. Rest of Middle East & Africa: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 71. South & Central America: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 72. South & Central America: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 73. South & Central America: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 74. Brazil: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 75. Brazil: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 76. Brazil: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 77. Argentina: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 78. Argentina: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 79. Argentina: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 80. Rest of South & Central America: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Product
- Table 81. Rest of South & Central America: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by Technology
- Table 82. Rest of South & Central America: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand) β by End User
- Table 83. Recent Organic Growth Strategies in the Therapeutic Vaccines Market
- Table 84. Recent Inorganic Growth Strategies in the Therapeutic Vaccines Market
- Table 85. Glossary of Terms, Therapeutic Vaccines Market
- LIST OF FIGURES
- Figure 1. Therapeutic Vaccines Market Segmentation, by Geography
- Figure 2. PEST Analysis
- Figure 3. Impact Analysis of Drivers and Restraints
- Figure 4. Therapeutic Vaccines Market Revenue (US$ Thousand), 2021β2031
- Figure 5. Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- Figure 6. Therapeutic Vaccines Market Share (%) β by Product (2024 and 2031)
- Figure 7. Cancer Vaccines: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- Figure 8. Infectious Disease Vaccines: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- Figure 9. Others: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- Figure 10. Therapeutic Vaccines Market Share (%) β by Technology (2024 and 2031)
- Figure 11. Allogenic Vaccine: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- Figure 12. Autologous Vaccine: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- Figure 13. Therapeutic Vaccines Market Share (%) β by End User (2024 and 2031)
- Figure 14. Hospitals: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- Figure 15. Clinics: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- Figure 16. Others: Therapeutic Vaccines Market β Revenue and Forecast to 2031 (US$ Thousand)
- Figure 17. North America: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 18. North America: Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
- Figure 19. United States: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 20. Canada: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 21. Mexico: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 22. Europe: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 23. Europe: Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
- Figure 24. Germany: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 25. United Kingdom: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 26. France: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 27. Italy: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 28. Spain: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 29. Rest of Europe: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 30. Asia Pacific: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 31. Asia Pacific: Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
- Figure 32. China: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 33. Japan: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 34. India: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 35. South Korea: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 36. Australia: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 37. Rest of APAC: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 38. Middle East & Africa: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 39. Middle East & Africa: Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
- Figure 40. Saudi Arabia: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 41. South Africa: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 42. United Arab Emirates: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 43. Rest of Middle East & Africa: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 44. South & Central America: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 45. South & Central America: Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
- Figure 46. Brazil: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 47. Argentina: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 48. Rest of South & Central America: Therapeutic Vaccines Market β Revenue and Forecast to 2031(US$ Thousand)
- Figure 49. Growth Strategies in the Therapeutic Vaccines Market
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.